Nitric oxide donors showed no clear difference in caesarean section compared with placebo (moderate certainty).
Nitric oxide donors showed no clear difference in serious neonatal morbidity/perinatal death compared with placebo (low certainty).
It is very uncertain whether PGE2 changes vaginal delivery not achieved within 24 hours compared with placebo or no treatment (very low certainty).
(4.1) PGE2 gel showed no clear difference in instrumental vaginal delivery compared with PGE2 tablet (all women) (moderate certainty).
(7.1) PGE2 (controlled release) showed no clear difference in vaginal delivery not achieved within 24 hours compared with all PGE2 delivery systems (all women) (moderate certainty).
(7.1) PGE2 (controlled release) showed no clear difference in uterine hyperstimulation with FHR changes compared with all PGE2 delivery systems (all women) (moderate certainty).
(7.1) PGE2 (controlled release) showed no clear difference in caesarean section compared with all PGE2 delivery systems (all women) (moderate certainty).
(7.1) PGE2 (controlled release) showed no clear difference in serious neonatal morbidity or perinatal death compared with all PGE2 delivery systems (all women) (low certainty).
PGE2 probably leads to higher uterine hyperstimulation with FHR changes compared with placebo or no treatment (moderate certainty).
PGE2 showed no clear difference in caesarean section compared with placebo or no treatment (high certainty).
PGE2 showed no clear difference in serious neonatal morbidity or perinatal death compared with placebo or no treatment (low certainty).
It is very uncertain whether PGE2 changes serious maternal morbidity or death compared with placebo or no treatment (very low certainty).
(4.1) PGE2 gel showed no clear difference in vaginal delivery not achieved within 24 hours compared with PGE2 tablet (all women) (moderate certainty).
It is very uncertain whether (4.1) PGE2 gel changes uterine hyperstimulation with FHR changes compared with PGE2 tablet (all women) (very low certainty).
(4.1) PGE2 gel showed no clear difference in caesarean section compared with PGE2 tablet (all women) (high certainty).
(4.1) PGE2 gel showed no clear difference in serious maternal morbidity or death compared with PGE2 tablet (all women); GRADE not reported.
Discontinued intravenous (IV) oxytocin stimulation may leads to lower caesarean delivery compared with continued IV oxytocin stimulation (low certainty).
Discontinued intravenous (IV) oxytocin stimulation showed no clear difference in caesarean delivery after active phase has begun, using "reached… compared with continued IV oxytocin stimulation (moderate certainty).
Discontinued intravenous (IV) oxytocin stimulation probably leads to lower uterine tachysystole combined with abnormal fetal heart rate compared with continued IV oxytocin stimulation (moderate certainty).